ID | 62782 |
JaLCDOI | |
フルテキストURL | |
著者 |
Sadahira, Takuya
Department of Urology, Okayama University Hospital
Maruyama, Yuki
Department of Urology, Okayama University Hospital
Hiyama, Yoshiki
Hakodate Goryoukaku Hospital
Kitano, Hiroyuki
Hiroshima University Hospital
Yamada, Hiroki
Jikei University Katsushika Medical Center
Goto, Takayuki
Kyoto University Hospital
Kondo, Tsubasa
Nagasaki University Hospital
Shigemura, Katsumi
Kobe University Hospital
Mitsui, Yosuke
Department of Urology, Okayama University Hospital
Iwata, Takehiro
Department of Urology, Okayama University Hospital
Edamura, Kohei
Department of Urology, Okayama University Hospital
Araki, Motoo
Department of Urology, Okayama University Hospital
Watanabe, Masami
Department of Urology, Okayama University Hospital
Takenaka, Tadasu
Japanese Red Cross Okayama Hospital
Teishima, Jun
Hiroshima University Hospital
Miyata, Yasuyoshi
Nagasaki University Hospital
Ishikawa, Kiyohito
Fujita Health University Hospital
Takaoka, Ei-Ichiro
Internationla University of Health and Welfare Hospital
Miyazaki, Jun
Internationla University of Health and Welfare Hospital
Takahashi, Satoshi
Sapporo Medical University Hospital
Masumori, Naoya
Sapporo Medical University Hospital
Kiyota, Hiroshi
Jikei University Katsushika Medical Center
Fujisawa, Masato
Kobe University Hospital
Yamamoto, Shingo
Hyogo College of Medicine College Hospital
Sakuma, Takafumi
Okayama Medical Center
Kusumi, Norihiro
Okayama Medical Center
Ichikawa, Takaharu
Okayama Medical Center
Watanabe, Toyohiko
Department of Urology, Okayama University Hospital
Nasu, Yoshitsugu
Okayama Rosai Hospital
Tsugawa, Masaya
Okayama City General Medical Center
Nasu, Yasutomo
Department of Urology, Okayama University Hospital
Wada, Koichiro
Department of Urology, Okayama University Hospital
|
抄録 | The aim of this report is to introduce an on-going, multicenter, randomized controlled trial to evaluate whether tailored antimicrobial prophylaxis guided by rectal culture screening prevents acute bacterial prostatitis following transrectal prostate biopsy (TRPB). Patients will be randomized into an intervention or non-intervention group; tazobactam-piperacillin or levofloxacin will be prophylactically administered according to the results of rectal culture prior to TRPB in the intervention group whereas levofloxacin will be routinely given in the non-intervention group. The primary endpoint is the occurrence rate of acute bacterial prostatitis after TRPB. Recruitment begins in April, 2021 and the target total sample size is 5,100 participants.
|
キーワード | antibiotic prophylaxis
selective culture media
prostate biopsy
fluoroquinolone-resistant
extended- spectrum beta-lactamase
|
Amo Type | Clinical Study Protocol
|
出版物タイトル |
Acta Medica Okayama
|
発行日 | 2021-10
|
巻 | 75巻
|
号 | 5号
|
出版者 | Okayama University Medical School
|
開始ページ | 663
|
終了ページ | 667
|
ISSN | 0386-300X
|
NCID | AA00508441
|
資料タイプ |
学術雑誌論文
|
言語 |
英語
|
著作権者 | CopyrightⒸ 2021 by Okayama University Medical School
|
論文のバージョン | publisher
|
査読 |
有り
|
PubMed ID | |
Web of Science KeyUT | |
NAID |